Please enter the email address you used to register, then we will send you a link to choose a new password
BioCardia shares are trading lower by 12% during Friday's session. The company announced the pricing of an upsized public o...
BioCardia shares are trading higher by 95% during Thursday's session. The FDA cleared the company to market its Morph DNA S...
BCDA: 162% | BioCardia shares are trading higher after FDA cleared the company to market its Morph DNA Steerable Introducer pro...
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy and maintains $25 price target.
HC Wainwright & Co. analyst Joseph Pantginis maintains BioCardia (NASDAQ:BCDA) with a Buy, adjusts target to $25 from $4 (1...
BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.88) per share. The company reported quarterly sales of $3.000 thousan...
This product family is intended to provide a pathway through which medical instruments, such as balloon dilatation catheters, g...
HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy and maintains $4 price target.
BioCardia, Inc. (NASDAQ:BCDA), a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular...